Slide 1: Exchange filing cover letter
15 May 2026 To To National Stock Exchange of India Limited BSE Limited Exchange Plaza, C-1, Block G, Bandra Kurla Phiroze Jeejeebhoy Towers, Dalal Street Complex, Bandra (E), Mumbai – 400 051 Mumbai – 400001 NSE Scrip Symbol: SaiLife BSE Scrip Code: 544306 Sub: Investor Presentation for the quarter
Slide 2: Sai Life Sciences Investor Presentation
Sai Life Sciences Investor Presentation May 15, 2026 All rights reserved © 2026 Sai Life Sciences Limited 1 All rights reserved © 2026 Sai Life Sciences Limited
Slide 3: Safe Harbour
Safe Harbour Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as "will", "aim", "will likely result", "would", "believe", "may", "expect", "will continue", "anticipate", "estimate", "intend", "
Slide 4: Message from Mr. Krishna Kanumuri, MD & CEO
FY26 was an important year for Sai Life Sciences as we continued to deepen our relationships with global pharma customers, expand our integrated CRDMO capabilities, and invest for the next phase of growth. While the operating environment remains dynamic, we believe the long-term fundamentals of inno
Slide 5: Message from Mr. Siva Chittor, CFO
FY26 reflected strong execution across the business, supported by healthy growth in both revenues and EBITDA. We are doubling-down on our Capex spend in FY27, with a ₹1100-1300 Crore allocation, which is closely aligned with customer demand and long-term strategic opportunities. - Mr. Siva Chittor W
Slide 6: Executive Summary
“ Sai Make it better together Executive Summary
Slide 7: Structural Industry Drivers And Sai Positioning
Structural Industry Drivers And Sai Positioning Rise in R&D and Geographic Biotech Funding Strategic Manufacturing Outsourcing Diversification Recovery Partnerships • Increasing outsourcing • Trend of Large Pharma • Biotech funding • Large Pharma intensity across Pharma & diversifying supply chains
Slide 8: Fueling Growth Through Strategic Capex
Fueling Growth Through Strategic Capex Entering a front-loaded investment cycle aligned with long-term customer demand and strategic growth opportunities FY26 Capex FY27 Capex ₹633 Crore Against budget of ₹700 crore ₹1,100 – 1,300 Crore SPLIT BY BUSINESS FY27 SPEND AREAS Capacity Expansion ~75% 70%
Slide 9: Business Updates
Business Updates Deepening Large Pharma Engagement • Increasing strategic engagement with global large pharma customers across CRO and CDMO • Dedicated R&D team models gaining strong traction • Expansion of relationships from early discovery to commercial manufacturing • Commercial supply qualificat
Slide 10: External Environment & Industry Developments
External Environment & Industry Developments MIDDLE EASTERN CONFLICT TARIFF ENVIRONMENT Ongoing geopolitical tensions have Evolving tariff environment remains led to a rise in input and logistics costs an area of focus Sai has initiated customer discussions From Sai’s perspective, no impact for appr
Slide 11: Consolidated Financial Highlights
Consolidated Financial Highlights Revenue (₹ Cr) Material Margin (₹ Cr) and Margin (%) EBITDA* (₹ Cr) and Margin (%) PAT * (₹ Cr) and Margin (%) 30.1% 72.5% 73.9% 16.2% 2,192 25.1% 10.0% 355 1,622 661 1,695 1,229 425 29% 32% 56% 109% YoY YoY YoY 170 YoY FY25 FY26 FY25 FY26 FY25 FY26 FY25 FY26 FY26 R
Slide 12: Sustained Growth Momentum with Expanding Profitability
Sustained Growth Momentum with Expanding Profitability (Consolidated) 30% 25% 2,192 20% Positioned to 15% 15% 1,695 achieve 15-20% 1,465 revenue CAGR over 1,217 3-5 years* & 28-30% 870 EBITDA margins in the next 2-3 years* FY22 FY23 FY24 FY25 FY26 IPO Revenue (₹ Cr) EBITDA Margin (%) The Company rem
Slide 13: 5-Years KPI Trend
5-Years KPI Trend Revenue (₹ Cr) EBITDA* (₹ Cr) and Margin (%) PAT* (₹ Cr) and Margin (%) 30% 16% 2,192 25% 10% 1,695 20% 6% 1,465 661 1,217 16% 14% 1% 1% 355 870 425 300 182 170 131 6 10 83 FY22 FY23 FY24 FY25 FY26 FY22 FY23 FY24 FY25 FY26 FY22 FY23 FY24 FY25 FY26 ROCE ROE Net Fixed Asset Turnover
Slide 14: Company Overview
“ Sai Make it better together Company Overview
Slide 15: Sai Life Sciences: At a Glance
Sai Life Sciences: At a Glance Integrated CRDMO Outsourcing Offer complete Contract Research, partner to services from Development and pharma drug discovery to Manufacturing innovators manufacturing Organization 27 Years Global Partner Expansive Innovation-Led of Expertise of Choice Infrastructure G
Slide 16: Key Highlights
Key Highlights Fastest growing NSE/BSE 3,800+ 300+ Indian CRDMO Listed on the Indian Total employees Active customers across Stock Exchanges in US, UK, EU, Japan over the last 5 years Dec 2024 11+ years 19/25* USFDA, PMDA Diverse Average tenure of large of the largest pharmaceutical pharma relations
Slide 17: Our Growth Journey
Our Growth Journey 1999 - 2008 2009 – 2013 2014 – 2018 2019 – 2023 2024 – Present Founding & CDMO Biology Foray; CDMO Globalization, Scaled-up Increasing Capacity & Early Biotech Foray Pivot Consolidation Integrated CRDMO Strengthening New-Age Modalities • Incorporated in 1999; began as a • First US
Slide 18: Global Presence
Global Presence Research laboratories for discovery and development located near overseas innovation hubs in Greater Global Team Boston, US and Manchester, UK, complemented by large-scale research laboratories and manufacturing facilities in cost competitive locations in India. 3,800+ Bidar, India E
Slide 19: A leading Integrated CRDMO
A leading Integrated CRDMO Sai Life Sciences operates as both a CRO and a CDMO, offering an end-to-end platform for global pharmaceutical and biotech companies Seamless Mid to Tox to early phase supplies late phase supplies Integration One-stop solution Commercial supplies from research to commercia
Slide 20: End-to-end Capabilities, Small Molecule Focus
End-to-end Capabilities, Small Molecule Focus Discovery Development Manufacturing From target ID & validation to IND Stage Complex chemical synthesis from • 700 KL Capacity with manufacturing Blocks through Creative Chemistry, Complex development to commercialization. • 80 Production trains Biology,
Slide 21: Discovery Services spanning Target Validation to IND
Discovery Services spanning the entire journey from Target Validation to IND Integrated services: Synthetic & Medicinal Chemistry, CADD, Biology, DMPK and Toxicology Lead Candidate n Ma sig ke / De Ch Target Evaluation em In vivo Pharmacology istr y Analyze HIT ID Toxicology PK M D y & Test / Bi o l
Slide 22: Discovery Services (CRO)
Discovery Services (CRO) Consistent Revenue Growth (₹ Cr) 775 626 Client Stickiness Automation Modalities Expansion 467 497 274 >65% Revenues from Focus on automation Expanding capabilities customers in FY23-26 and scale in DMPK and in ADCs, TPDs, FY22 FY23 FY24 FY25 FY26 who availed more than biolo
Slide 23: Discovery Services: Scaling Innovation, Driving Impact
Discovery Services: Scaling Innovation, Driving Impact >65% of Discovery programs are now integrated, with active use of next-gen biology, automation, and AI to accelerate development and improve outcomes Expanded Core Colocalized & Tech-Enabled Drug Specialized Next-Gen Capabilities Global Teams Di
Slide 24: Development Services from H2L to Commercial Supply
Development Services from H2L to Commercial Supply Underpinned by integrated scientific approaches applied in a phase-appropriate manner • Continuous Verification • Control • Continuous Strategy Improvement • Process Definition Optimization Lifecycle • API Developability & Design Strategy Commercial
Slide 25: CMC Services (CDMO)
CMC Services (CDMO) • End-to-End capabilities from IND through to commercialization Consistent Revenue Growth (₹ Cr) • Focus on Complex Chemistry, ADC Payloads & Linkers • Modern, GMP-compliant facilities across UK and India 1,417 • Flexibility to support both small-scale clinical supplies and large
Slide 26: New Modalities: Fortifying foundation to build scale
New Modalities: Fortifying foundation to build scale Peptides Antibody-Drug Conjugates Complement peptide discovery with Enhancing conjugation in Discovery; New Modalities Revenue Contribution (%) upgrading to class 6 containment for process and scale-up facilities for clinical supplies; focus on co
Slide 27: Our Strengths
“ Sai Make it better together Our Strengths
Slide 28: Information Technology - Driven Excellence: Digitization & Beyond
Information Technology - Driven Excellence: Digitization & Beyond Digitization Digitalization Digital Transformation 2017 onwards 2022 onwards 2023 onwards Converting data, documents and processes Use of digitized data for effective monitoring integration of digital technologies into all from paper/
Slide 29: Global-Standard Operations, End-to-End
Global-Standard Operations, End-to-End Quality Assurance Sustainability Leadership Safety & EHS Leadership • 300+ QA/QC professionals • 100% renewable energy at • Embedded Process Safety from across sites Bidar site quote to execution phase; • Integrated e-systems: LIMS, e- • Zero Liquid Discharge:
Slide 30: Key Drivers for Growth
Key Drivers for Growth Scaling Capacity & Infrastructure Diversifying Portfolio Scientific & Talent Leadership • The company has incurred ₹633 Cr • 45 active molecules* –34 commercial, • Driving global program transfers to India capex in FY26 to enhance manufacturing with 11 Phase III / pre registra
Slide 31: Annexure
“ Sai Make it better together Annexure
Slide 32: Consolidated Statement of Profit and Loss
Consolidated Statement of Profit and Loss Particulars (₹ Cr) Q4FY26 Q3FY26 Q4FY25 FY26 FY25 Revenue from operations 602 556 580 2192 1695 Other income 3 5 6 19 18 Total income 605 561 586 2212 1712 Expenses Cost of materials consumed and changes in inventories 162 128 168 571 466 Employee benefits e
Slide 33: Consolidated Balance Sheet
Consolidated Balance Sheet Assets (₹ Cr) Mar 26 Mar 25 Equity and Liabilities (₹ Cr) Mar 26 Mar 25 Non current assets Property, plant, and equipment 1,534 1,185 Equity share capital 21 21 Right of use of assets 274 292 Other equity 2,463 2,108 Capital work in progress 270 124 Total equity 2,484 2,12
Slide 34: Awards Certificates & Accreditations
Awards Certificates & Accreditations Member of: Accelerating the Discovery, ISO 14001:2015, ISODevelopment 45001:2018, and Manufacturing of small ISO 50001:2018, ISOmolecules 27001:2022 & ISO 28000:2022 certifications Certificate of Registration: Information Certified for Social Accountability and S
Slide 35: Glossary
Glossary APIs Active pharmaceutical ingredients Biotechnology companies, often referred to as biotech companies, are largely startups in the pharmaceutical sector which typically focus on developing innovative drugs and drug Biotechs development technologies to address unmet medical needs Blockbuste
Slide 36: Thank You
Thank You For more details please contact: Investorrelation@sailife.com © Sai Life Sciences Limited. L4, SLN Terminus, Gachibowli, Hyderabad 500032, Telangana, India.